STOCK TITAN

[144] BICYCLE THERAPEUTICS PLC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Bicycle Therapeutics plc (BCYC) filed a Form 144 notice reporting a proposed sale of 102 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $872, intended for sale on 10/02/2025 on Nasdaq. The filing discloses that 218 shares were acquired on 10/02/2025 as Restricted Stock Units from the issuer and were paid as equity compensation. The form also reports that the filer sold 411 shares on 07/02/2025 for gross proceeds of $3,058. The notice includes the statutory representation that the seller does not possess undisclosed material adverse information about the issuer.

Bicycle Therapeutics plc (BCYC) ha presentato un Modulo 144 di avviso riportando una potenziale vendita di 102 azioni ordinarie tramite Stifel Nicolaus & Company Inc con un valore di mercato aggregato di $872, prevista per la vendita il 02/10/2025 su Nasdaq. L'avviso indica che 218 azioni sono state acquisite il 02/10/2025 come Unità Azionarie Vincolate da parte dell'emittente e sono state pagate come compensazione azionaria. Il modulo riporta inoltre che il dichiarante ha venduto 411 azioni il 07/02/2025 per proventi lordi di $3,058. L'avviso comprende la dichiarazione legale secondo cui il venditore non possiede informazioni materiali rilevanti non divulgate sull'emittente.

Bicycle Therapeutics plc (BCYC) presentó un aviso Form 144 informando de una venta propuesta de 102 acciones comunes a través de Stifel Nicolaus & Company Inc con un valor de mercado agregado de $872, prevista para la venta el 10/02/2025 en Nasdaq. El escrito divulga que 218 acciones fueron adquiridas el 02/10/2025 como Restricted Stock Units de la emisor y fueron pagadas como compensación en acciones. El formulario también informa que el declarante vendió 411 acciones el 07/02/2025 por ingresos brutos de $3,058. El aviso incluye la declaración estatutaria de que el vendedor no posee información material adversa no divulgada sobre la emisor.

Bicycle Therapeutics plc (BCYC)Form 144 통지서를 제출하여 Stifel Nicolaus & Company Inc를 통해 102 주식 보통주를 매도하려는 계획을 공개했고 총 시장가치는 $872이며, Nasdaq에서 2025-10-02에 매도할 예정입니다. 해당 신고는 218 주식이 발행사로부터 Restricted Stock Units2025-10-02에 취득되었으며 주식 보상로 지급되었음을 밝힙니다. 또한 양식은 공시인이 411 주식을 2025-07-02에 매각하여 총처분가가 $3,058임을 보고합니다. 통지에는 발행사에 대한 미공개 중대정보를 보유하지 않는다는 법적 진술이 포함되어 있습니다.

Bicycle Therapeutics plc (BCYC) a déposé un avis Form 144 indiquant une vente proposée de 102 actions ordinaires par l'intermédiaire de Stifel Nicolaus & Company Inc ayant une valeur marchande globale de $872, prévue pour être vendue le 02/10/2025 sur Nasdaq. Le document précise que 218 actions ont été acquises le 02/10/2025 en tant que Restricted Stock Units de l'émetteur et ont été rémunérées sous forme de rémunération en actions. Le formulaire indique également que le déclarant a vendu 411 actions le 07/02/2025 pour un produit brut de $3,058. L'avis comprend la déclaration statutaire selon laquelle le vendeur ne possède pas d'informations matérielles défavorables non divulguées concernant l'émetteur.

Bicycle Therapeutics plc (BCYC) hat eine Form 144-Mitteilung eingereicht, die einen vorgeschlagenen Verkauf von 102 Stammaktien über Stifel Nicolaus & Company Inc mit einem aggregierten Marktwert von $872 vorsieht, der am 02.10.2025 auf Nasdaq erfolgen soll. Die Einreichung gibt an, dass 218 Aktien am 02.10.2025 als Restricted Stock Units vom Emittenten erworben wurden und als Eigenkapitalvergütung bezahlt wurden. Das Formular berichtet auch, dass der Antragsteller am 02.07.2025 411 Aktien zu Bruttoerlösen von $3,058 verkauft hat. Die Mitteilung enthält die gesetzliche Zusicherung, dass der Verkäufer keine nicht offengelegten wesentlichen nachteiligen Informationen über den Emittenten besitzt.

Bicycle Therapeutics plc (BCYC) قدمت إشعاراً من Form 144 يوضح بيعاً مقترحاً لـ 102 سهمًا من الأسهم العادية عبر Stifel Nicolaus & Company Inc بقيمة سوقية إجمالية قدرها $872، والمقرر بيعه في 02/10/2025 على Nasdaq. يكشف الإبلاغ أن 218 سهماً تم اكتسابها في 02/10/2025 كـ Restricted Stock Units من المصدر ودفعت كتعويض سهمي. كما يذكر النموذج أن المبلغ لديه باع 411 سهماً في 07/02/2025 بعوائد إجمالية قدرها $3,058. يتضمن الإشعار التصريح القانوني بأن البائع لا يمتلك معلومات مادية سلبية غير معلنة عن المصدر.

Bicycle Therapeutics plc (BCYC) 提交了一份 Form 144 通知,报告通过 Stifel Nicolaus & Company Inc 计划通过以 102 股普通股在 Nasdaq 上以总市值 $872 进行出售,预计于 2025/10/02 出售。该申报披露,218 股于 2025/10/02Restricted Stock Units 形式从发行方取得,作为< b>股权补偿 发放。表格还报告,申报人于 2025/07/02 出售了 411 股,毛收入为 $3,058。通知还包括法定陈述:卖方不持有关于发行人的未披露的重大不利信息。

Positive
  • Form 144 was filed, disclosing the proposed sale of 102 shares
  • Broker named: Stifel Nicolaus & Company Inc
  • Acquisition of 218 shares on 10/02/2025 was via Restricted Stock Units and paid as equity compensation
  • Previous sale disclosed: 411 shares sold on 07/02/2025 for $3,058
Negative
  • None.

Insights

Form 144 filed to report an insider's proposed sale of 102 shares for $872 on 10/02/2025.

The filing identifies the broker as Stifel Nicolaus & Company Inc and specifies the market where the shares will be sold: Nasdaq. It also documents the acquisition of 218 shares on 10/02/2025 as Restricted Stock Units paid via equity compensation.

The form lists a prior disposition of 411 shares on 07/02/2025 producing $3,058 in gross proceeds. This information is procedural disclosure required under Rule 144 and confirms compliance steps for an insider sale; no additional material facts or regulatory actions are disclosed in the filing.

Bicycle Therapeutics plc (BCYC) ha presentato un Modulo 144 di avviso riportando una potenziale vendita di 102 azioni ordinarie tramite Stifel Nicolaus & Company Inc con un valore di mercato aggregato di $872, prevista per la vendita il 02/10/2025 su Nasdaq. L'avviso indica che 218 azioni sono state acquisite il 02/10/2025 come Unità Azionarie Vincolate da parte dell'emittente e sono state pagate come compensazione azionaria. Il modulo riporta inoltre che il dichiarante ha venduto 411 azioni il 07/02/2025 per proventi lordi di $3,058. L'avviso comprende la dichiarazione legale secondo cui il venditore non possiede informazioni materiali rilevanti non divulgate sull'emittente.

Bicycle Therapeutics plc (BCYC) presentó un aviso Form 144 informando de una venta propuesta de 102 acciones comunes a través de Stifel Nicolaus & Company Inc con un valor de mercado agregado de $872, prevista para la venta el 10/02/2025 en Nasdaq. El escrito divulga que 218 acciones fueron adquiridas el 02/10/2025 como Restricted Stock Units de la emisor y fueron pagadas como compensación en acciones. El formulario también informa que el declarante vendió 411 acciones el 07/02/2025 por ingresos brutos de $3,058. El aviso incluye la declaración estatutaria de que el vendedor no posee información material adversa no divulgada sobre la emisor.

Bicycle Therapeutics plc (BCYC)Form 144 통지서를 제출하여 Stifel Nicolaus & Company Inc를 통해 102 주식 보통주를 매도하려는 계획을 공개했고 총 시장가치는 $872이며, Nasdaq에서 2025-10-02에 매도할 예정입니다. 해당 신고는 218 주식이 발행사로부터 Restricted Stock Units2025-10-02에 취득되었으며 주식 보상로 지급되었음을 밝힙니다. 또한 양식은 공시인이 411 주식을 2025-07-02에 매각하여 총처분가가 $3,058임을 보고합니다. 통지에는 발행사에 대한 미공개 중대정보를 보유하지 않는다는 법적 진술이 포함되어 있습니다.

Bicycle Therapeutics plc (BCYC) a déposé un avis Form 144 indiquant une vente proposée de 102 actions ordinaires par l'intermédiaire de Stifel Nicolaus & Company Inc ayant une valeur marchande globale de $872, prévue pour être vendue le 02/10/2025 sur Nasdaq. Le document précise que 218 actions ont été acquises le 02/10/2025 en tant que Restricted Stock Units de l'émetteur et ont été rémunérées sous forme de rémunération en actions. Le formulaire indique également que le déclarant a vendu 411 actions le 07/02/2025 pour un produit brut de $3,058. L'avis comprend la déclaration statutaire selon laquelle le vendeur ne possède pas d'informations matérielles défavorables non divulguées concernant l'émetteur.

Bicycle Therapeutics plc (BCYC) hat eine Form 144-Mitteilung eingereicht, die einen vorgeschlagenen Verkauf von 102 Stammaktien über Stifel Nicolaus & Company Inc mit einem aggregierten Marktwert von $872 vorsieht, der am 02.10.2025 auf Nasdaq erfolgen soll. Die Einreichung gibt an, dass 218 Aktien am 02.10.2025 als Restricted Stock Units vom Emittenten erworben wurden und als Eigenkapitalvergütung bezahlt wurden. Das Formular berichtet auch, dass der Antragsteller am 02.07.2025 411 Aktien zu Bruttoerlösen von $3,058 verkauft hat. Die Mitteilung enthält die gesetzliche Zusicherung, dass der Verkäufer keine nicht offengelegten wesentlichen nachteiligen Informationen über den Emittenten besitzt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Bicycle Therapeutics' (BCYC) Form 144 report?

The form reports a proposed sale of 102 shares of common stock through Stifel Nicolaus with an aggregate market value of $872, to be sold on 10/02/2025 on Nasdaq.

How were the securities that may be sold acquired?

The filing states 218 shares were acquired on 10/02/2025 as Restricted Stock Units from the issuer and paid as equity compensation.

Did the filer sell any BCYC shares recently?

Yes. The filing discloses a prior sale of 411 shares on 07/02/2025 that generated $3,058 in gross proceeds.

Which broker will handle the proposed sale?

The proposed sale lists Stifel Nicolaus & Company Inc as the broker.

On which exchange is the sale intended to occur?

The form specifies the sale is intended to occur on Nasdaq.
Bicycle Therapeutics Limited

NASDAQ:BCYC

BCYC Rankings

BCYC Latest News

BCYC Latest SEC Filings

BCYC Stock Data

554.45M
49.07M
1.4%
88.35%
2.29%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
CAMBRIDGE